IXA 2025 - Mobis

P2.34 Multiplex gene-edited porcine corneal xenotransplantation in Tibetan macaques: Immune rejection mechanisms

Dr. Xiaoming Yao, People's Republic of China

P2.01 Legal gaps in the regulation of xenotransplantation using genetically engineered pigs: A case study of the South Korean legal framework

Miss Jungbeen Lee, Korea

P2.02 Profile and attitudes of high school students (São Paulo city, Brazil) toward xenotransplantation

Mrs. Ludmila Garcia, Brazil

P2.03 Establishment of a designated pathogen-free (DPF)-unit in Germany

Maria V. Leuschen, Germany

P2.04 Histocompatibility testing in preclinical cardiac xenotransplantation

Maria V. Leuschen, Germany

P2.05 Ferroptosis in pig-to-baboon cardiac xenotransplantation

Dr. Martin Bender, Germany

P2.06 How important is the Fc-portion for CD40/CD40L costimulation blockade in orthotopic pig-to-baboon heart transplantation?

Matthias Längin, Germany

P2.07 The endothelial glycocalyx in pig-to-baboon cardiac xenotransplantation – First insights

Dr. Martin Bender, Germany

P2.08 Renal arterial resistive index identifies thrombotic microangiopathy after kidney xenotransplantation in pig-to-baboon model

Dr. Sho Fujiwara, United States

P2.09 Cell-free DNA method for monitoring porcine-to-human xenotransplants

Dr. Philippe Gauthier, United States

P2.10 Selectin/Integrin blockade and macrophage depletion mitigate injury in pig lung xenoperfusion with human blood

Dr. Zahra A. Habibabady, United States

P2.11 Blockade of CD40 with or without CD11b versus CD154 blockade in GTKO and hCD55 transgenic pig-to-macaque kidney xenotransplantation

Dr. Bryar Hansen, United States

P2.12 Prognostic factor analysis for xenocorneal anterior lamellar transplantation using genetically-modified pig

Dr. Sun Ae Hwang, Korea

P2.13 Immunotherapy strategies for clinical approval in kidney xenotransplantation

Dr. Sun Ae Hwang, Korea

P2.14 Effect of high-dose steroid therapy on graft survival and inflammatory markers in nonhuman primate recipients of genetically modified porcine kidney xenografts

Prof. Hee Jung Kang, Korea

P2.15 Enhanced graft survival in full-thickness corneal xenotransplantation from glycan or complement gene-edited pigs to non-human primates

Prof. Chung Young Kim, Korea

P2.16 Impact of increased dose of anti-CD154 monoclonal antibody on graft survival in pig-to-baboon kidney xenotransplantation

Dr. Kohei Kinoshita, United States

P2.17 Dual-purpose xenogeneic lung perfusion: Towards xeno- and allo-lung transplantation

Dr. Robert Ramm, Germany

P2.18 Exploring macrophage responses in porcine - human lung xenotranplantation: Interplay of cytokine signalling and glycan dynamics

Dr. Robert Ramm, Germany

P2.19 To investigate the changing trends in cardiac function following xenogeneic heterotopic heart transplantation of multi-gene edited pig hearts and assess the impact of recipient immune responses on donor heart, laying experimental groundwork for the clinical application of gene editing technology

Dr. Zhipeng Ren, People's Republic of China

P2.20 Influence of gene knockouts and human transgenes on the interaction between human blood and porcine lung-derived endothelial cells in the context of pulmonary xenotransplantation

Ms. Yandra Rode, Germany

P2.21 Xenoperfusion of triple glycan knock-out, seven human transgene insertion porcine livers with human whole blood

Mr. Alex Sagar, United Kingdom

P2.22 Management of pleural effusions following orthotopic cardiac xenotransplantation in a pediatric non-human primate model

Dr. William B Swicord, United States

P2.23 Experimental study on transplantation of transgenic edited pig-primate transplantation of heterotopic hearts

Dr. Huan Wang, People's Republic of China

P2.24 Comparison of three double costimulatory blockade regiments for suppressing xenograft rejection in pig-to-nonhuman primate kidney xenotransplantation

Dr. IL-HEE YUN, Korea

P2.25 Development of proteinuria following 4GE Pig-to-rhesus monkey kidney xenotransplantation leads to loss of anti-CD154 antibody and accelerates the process of AMR

Dr. Man Zhang, People's Republic of China

P2.26 Endocrine function of life-supporting 10-gene-edited porcine kidneys in a nonhuman primate xenotransplantation model

Dr. Daniel L Eisenson, United States

P2.27 Source specific peripheral blood mononuclear cells may be more sensitive than aortic endothelial cells for detection of anti-pig antibodies in pig-to-baboon xenotransplantation

Dr. Daniel L Eisenson, United States

P2.28 HLA-sensitized human sera retain cross-reactivity to genetically modified porcine cells via SLA epitopes

Dr. Eunjee Oh, Korea

P2.29 Transforming swine leukocyte antigen (SLA) genotyping: Rapid and accurate determination of SLA alleles by long-read third-generation sequencing

Dr. Sam Ho, United States

P2.30 Characterization of SLAs in pig xenotransplant donors for personalized patients histocompatibility

Prof. Adrian Mutto, Argentina

P2.32 Innate immune–driven fibrotic remodeling as a key driver of chronic kidney xenograft injury

Prof. Minsun Jung, Korea

P2.33 Nursing care for brain-dead patients in xenotransplantation and xenotransfusion trials: Practical insights and challenges

Ms. Tiantian Zhao, People's Republic of China